Your daily dose of good news: Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial Experimental drug daraxonrasib delivered stunning Phase 3 results, nearly doubling survival (13.2 vs. 6.7 months) and cutting the risk of death

→ View original post on X — @kimmonismus,